Zevalin Used in Auto Stem Cell Transplant Effective for Chemo Resistant Aggressive NHL

Researchers from Israel reported at ASCO this week that the use of Zevalin (Yttrium 90 Ibritumomab Tiuxetan) used with high-dose chemotherapy and autologous stem cell transplant provides an effective treatment option for patients with aggressive non-Hodgkin’s lymphoma (NHL) in first or subsequent relapse.



Zevalin is a combination of Rituxan attached to the isotope Yttrium 90. The US Food and Drug Administration (FDA) has approved Zevalin for the treatment of patients with low-grade NHL that has stopped responding to standard therapies. The approval indicates that Zevalin must be used in combination with Rituxan®.



The trial presented at ASCO included 20 patients with a median age of 55 years whos NHL had become resistant to prior chemotherapy, with a median 3 prior regimens. NHL subtypes included mantle cell NHL, diffuse large cell and transformed follicular NHL.



14 patients achieved complete response (CR) and 4 achieved a partial response (PR).
Estimated one-year survival is nearly 60%.
Estimated one-year progression-free survival is 53%.
The day 100 treatment-related mortality was 10%.



The researchers concluded that the inclusion of Zevalin into high-dose chemotherapy regimens may improve disease-free survival and overall survival compared to high-dose chemotherapy and stem cell transplantation alone in patients with refractory, aggressive NHL. ASCO.org

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap